Trial Outcomes & Findings for Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (NCT NCT03856047)

NCT ID: NCT03856047

Last Updated: 2024-07-05

Results Overview

Change in body weight (%) from week 0 to week 26 is presented. For descriptive analysis and statistical analysis the endpoint was evaluated based on the data from in-trial period and treatment adherent period, respectively. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period. Treatment-adherent: a participant is treatment adherent until the first time of non-adherence defined as: participant has not been dosed with trial product within the prior 14 days; participant has received other weight management drug or bariatric surgery; participant has not reached target dose at a pre-specified week; After the pre-specified evaluation week for the target dose, the participant has not received the target dose ±10% within the prior 14 days.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 706 participants
• Primary outcome timeframe: From baseline (week 0) to week 26
• Results posted on: 2024-07-05

Participant Flow

The trial was conducted at 57 sites in 10 countries as follows: Canada (5), Denmark (2), Finland (4), Ireland (1), Japan (3), Poland (3), Serbia (5), South Africa (5), United Kingdom (7), United States of America (22).

Participants were randomized in a 6:1 ratio between the active treatment (cagrilintide and liraglutide) arms and the placebo arms. The five different cagrilintide placebo arms and the one liraglutide placebo arm were pooled into one placebo group in the main analyses. Participants received the treatments as an adjunct to reduced-calorie diet and increased physical activity.

Participant milestones

Measure	Cagrilintide 0.3 mg Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Overall Study STARTED	101	100	102	102	101	99	101
Overall Study Full Analysis Set	101	100	102	102	101	99	101
Overall Study Safety Analysis Set	101	100	102	102	101	99	101
Overall Study COMPLETED	97	97	98	101	94	95	95
Overall Study NOT COMPLETED	4	3	4	1	7	4	6

Reasons for withdrawal

Measure	Cagrilintide 0.3 mg Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Overall Study Withdrawal by Subject	0	1	1	0	3	0	2
Overall Study Lost to Follow-up	4	2	3	1	4	4	4

Baseline Characteristics

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Baseline characteristics by cohort

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=101 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.	Total n=706 Participants Total of all reporting groups
Age, Continuous	53.5 Years STANDARD_DEVIATION 10.3 • n=5 Participants	53.2 Years STANDARD_DEVIATION 11.0 • n=7 Participants	52.1 Years STANDARD_DEVIATION 8.7 • n=5 Participants	52.7 Years STANDARD_DEVIATION 9.8 • n=4 Participants	51.5 Years STANDARD_DEVIATION 12.7 • n=21 Participants	51.5 Years STANDARD_DEVIATION 9.3 • n=8 Participants	51.4 Years STANDARD_DEVIATION 11.9 • n=8 Participants	52.3 Years STANDARD_DEVIATION 10.6 • n=24 Participants
Sex: Female, Male Female	56 Participants n=5 Participants	62 Participants n=7 Participants	63 Participants n=5 Participants	75 Participants n=4 Participants	56 Participants n=21 Participants	65 Participants n=8 Participants	59 Participants n=8 Participants	436 Participants n=24 Participants
Sex: Female, Male Male	45 Participants n=5 Participants	38 Participants n=7 Participants	39 Participants n=5 Participants	27 Participants n=4 Participants	45 Participants n=21 Participants	34 Participants n=8 Participants	42 Participants n=8 Participants	270 Participants n=24 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	5 Participants n=8 Participants	4 Participants n=8 Participants	21 Participants n=24 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	99 Participants n=5 Participants	99 Participants n=7 Participants	98 Participants n=5 Participants	100 Participants n=4 Participants	98 Participants n=21 Participants	94 Participants n=8 Participants	97 Participants n=8 Participants	685 Participants n=24 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Race/Ethnicity, Customized White	77 Participants n=5 Participants	75 Participants n=7 Participants	75 Participants n=5 Participants	80 Participants n=4 Participants	83 Participants n=21 Participants	82 Participants n=8 Participants	71 Participants n=8 Participants	543 Participants n=24 Participants
Race/Ethnicity, Customized Asian	13 Participants n=5 Participants	14 Participants n=7 Participants	15 Participants n=5 Participants	11 Participants n=4 Participants	9 Participants n=21 Participants	13 Participants n=8 Participants	17 Participants n=8 Participants	92 Participants n=24 Participants
Race/Ethnicity, Customized Black or African American	9 Participants n=5 Participants	5 Participants n=7 Participants	8 Participants n=5 Participants	9 Participants n=4 Participants	5 Participants n=21 Participants	0 Participants n=8 Participants	9 Participants n=8 Participants	45 Participants n=24 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	2 Participants n=24 Participants
Race/Ethnicity, Customized Other	1 Participants n=5 Participants	5 Participants n=7 Participants	4 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants	4 Participants n=8 Participants	4 Participants n=8 Participants	24 Participants n=24 Participants

PRIMARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in body weight (%) from week 0 to week 26 is presented. For descriptive analysis and statistical analysis the endpoint was evaluated based on the data from in-trial period and treatment adherent period, respectively. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period. Treatment-adherent: a participant is treatment adherent until the first time of non-adherence defined as: participant has not been dosed with trial product within the prior 14 days; participant has received other weight management drug or bariatric surgery; participant has not reached target dose at a pre-specified week; After the pre-specified evaluation week for the target dose, the participant has not received the target dose ±10% within the prior 14 days.

Outcome measures

Measure	Cagrilintide 0.3 mg n=96 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=97 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=98 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=95 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Body Weight (%)	-6.1 Percentage point of body weight Standard Deviation 3.9	-6.9 Percentage point of body weight Standard Deviation 5.4	-8.5 Percentage point of body weight Standard Deviation 5.4	-9.5 Percentage point of body weight Standard Deviation 6.2	-10.8 Percentage point of body weight Standard Deviation 5.5	-8.5 Percentage point of body weight Standard Deviation 5.6	-3.0 Percentage point of body weight Standard Deviation 5.2

SECONDARY outcome

Timeframe: Week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Percentage of participants who achieved a weight loss of greater than or equal to (≥) 5% of baseline (week 0) body weight at 26 weeks is presented. The numbers presented are predictions from a logistic regression model.

Outcome measures

Measure	Cagrilintide 0.3 mg n=83 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=82 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=72 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=80 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=80 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=78 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=79 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 Weeks	57.47 Percentage of participants	61.98 Percentage of participants	75.84 Percentage of participants	74.12 Percentage of participants	88.74 Percentage of participants	76.16 Percentage of participants	30.90 Percentage of participants

SECONDARY outcome

Timeframe: Week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Percentage of participants who achieved a weight loss ≥ 10% of baseline (week 0) body weight at 26 weeks is presented. The numbers presented are predictions from a logistic regression model.

Outcome measures

Measure	Cagrilintide 0.3 mg n=83 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=82 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=72 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=80 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=80 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=78 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=79 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 Weeks	15.28 Percentage of participants	24.06 Percentage of participants	35.79 Percentage of participants	43.97 Percentage of participants	53.49 Percentage of participants	39.43 Percentage of participants	10.44 Percentage of participants

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in body weight (Kg) from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=96 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=97 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=98 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=95 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Body Weight (Kg)	-6.6 Kilograms (kg) Standard Deviation 4.3	-7.1 Kilograms (kg) Standard Deviation 5.6	-9.0 Kilograms (kg) Standard Deviation 6.3	-10.1 Kilograms (kg) Standard Deviation 6.7	-11.8 Kilograms (kg) Standard Deviation 6.8	-9.1 Kilograms (kg) Standard Deviation 6.4	-3.2 Kilograms (kg) Standard Deviation 5.8

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in waist circumference from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=96 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=97 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=98 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Waist Circumference	-6.2 centimeters (cm) Standard Deviation 5.0	-6.2 centimeters (cm) Standard Deviation 5.9	-7.7 centimeters (cm) Standard Deviation 7.1	-8.1 centimeters (cm) Standard Deviation 7.1	-9.5 centimeters (cm) Standard Deviation 6.1	-7.4 centimeters (cm) Standard Deviation 5.8	-3.4 centimeters (cm) Standard Deviation 5.7

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in total cholesterol from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Total Cholesterol	3.9 Milligrams per deciliter (mg/dL) Standard Deviation 27.8	-1.8 Milligrams per deciliter (mg/dL) Standard Deviation 22.1	-3.1 Milligrams per deciliter (mg/dL) Standard Deviation 24.9	-2.9 Milligrams per deciliter (mg/dL) Standard Deviation 26.7	-5.4 Milligrams per deciliter (mg/dL) Standard Deviation 22.1	-9.4 Milligrams per deciliter (mg/dL) Standard Deviation 26.4	0.1 Milligrams per deciliter (mg/dL) Standard Deviation 22.8

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in HDL cholesterol from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in High Density Lipoprotein (HDL) Cholesterol	1.5 mg/dL Standard Deviation 6.1	1.9 mg/dL Standard Deviation 6.9	1.1 mg/dL Standard Deviation 7.3	1.8 mg/dL Standard Deviation 5.6	2.6 mg/dL Standard Deviation 6.9	0.8 mg/dL Standard Deviation 6.3	0.1 mg/dL Standard Deviation 7.0

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in LDL cholesterol from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Low Density Lipoprotein (LDL) Cholesterol	5.2 mg/dL Standard Deviation 24.0	-0.3 mg/dL Standard Deviation 19.6	-0.5 mg/dL Standard Deviation 19.8	-0.9 mg/dL Standard Deviation 22.1	-2.7 mg/dL Standard Deviation 19.2	-5.4 mg/dL Standard Deviation 22.9	-1.0 mg/dL Standard Deviation 21.5

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in VLDL cholesterol from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Very Low Density Lipoprotein (VLDL) Cholesterol	-2.8 mg/dL Standard Deviation 9.1	-3.4 mg/dL Standard Deviation 11.9	-3.6 mg/dL Standard Deviation 14.1	-3.8 mg/dL Standard Deviation 9.4	-5.4 mg/dL Standard Deviation 10.2	-4.9 mg/dL Standard Deviation 8.6	0.9 mg/dL Standard Deviation 15.6

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in triglycerides from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=97 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Triglycerides	-13.29 mg/dL Standard Deviation 47.51	-16.25 mg/dL Standard Deviation 67.59	-17.98 mg/dL Standard Deviation 71.24	-19.24 mg/dL Standard Deviation 47.30	-30.35 mg/dL Standard Deviation 58.35	-25.42 mg/dL Standard Deviation 45.40	8.17 mg/dL Standard Deviation 103.36

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in HbA1c (measured as percentage point of HbA1c) from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=93 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=97 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Glycosylated Haemoglobin (HbA1c) (%-Point)	0.0 Percentage point of HbA1c Standard Deviation 0.2	-0.1 Percentage point of HbA1c Standard Deviation 0.2	-0.1 Percentage point of HbA1c Standard Deviation 0.3	-0.1 Percentage point of HbA1c Standard Deviation 0.3	-0.1 Percentage point of HbA1c Standard Deviation 0.2	-0.3 Percentage point of HbA1c Standard Deviation 0.2	-0.1 Percentage point of HbA1c Standard Deviation 0.2

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in HbA1c (measured as millimoles per mole (mmol/mol)) from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=93 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=97 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=95 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in HbA1c (mmol/Mol)	-0.5 mmol/mol Standard Deviation 2.4	-0.6 mmol/mol Standard Deviation 2.2	-0.8 mmol/mol Standard Deviation 3.0	-1.0 mmol/mol Standard Deviation 2.9	-1.2 mmol/mol Standard Deviation 2.4	-2.9 mmol/mol Standard Deviation 2.7	-0.6 mmol/mol Standard Deviation 2.7

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in FPG (measured as mmol/L)) from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=95 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=96 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=94 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Fasting Plasma Glucose (FPG) (mmol/L)	0.0 mmol/L Standard Deviation 0.6	0.0 mmol/L Standard Deviation 0.5	-0.2 mmol/L Standard Deviation 0.5	0.0 mmol/L Standard Deviation 0.7	-0.2 mmol/L Standard Deviation 1.0	-0.5 mmol/L Standard Deviation 0.7	0.0 mmol/L Standard Deviation 0.6

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in FPG (measured as milligrams per decilitre (mg/dL)) from week 0 to week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=95 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=96 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=94 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in FPG (mg/dL)	-0.7 mg/dL Standard Deviation 10.1	-0.6 mg/dL Standard Deviation 8.9	-3.2 mg/dL Standard Deviation 9.7	0.0 mg/dL Standard Deviation 12.0	-3.7 mg/dL Standard Deviation 18.4	-9.5 mg/dL Standard Deviation 12.4	-0.5 mg/dL Standard Deviation 11.7

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Number analysed = Number of participants who contributed to the analysis.

In the below table, fasting insulin data at week 0 and at week 26 is presented. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=101 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Fasting Insulin Week 0	103.88 Picomoles per liter (pmol/L) Standard Error 6.62	97.43 Picomoles per liter (pmol/L) Standard Error 6.73	96.44 Picomoles per liter (pmol/L) Standard Error 5.91	90.05 Picomoles per liter (pmol/L) Standard Error 4.70	109.99 Picomoles per liter (pmol/L) Standard Error 8.23	95.80 Picomoles per liter (pmol/L) Standard Error 5.73	105.77 Picomoles per liter (pmol/L) Standard Error 7.06
Change in Fasting Insulin Week 26	93.07 Picomoles per liter (pmol/L) Standard Error 6.44	82.98 Picomoles per liter (pmol/L) Standard Error 5.02	79.39 Picomoles per liter (pmol/L) Standard Error 4.53	71.22 Picomoles per liter (pmol/L) Standard Error 4.04	78.67 Picomoles per liter (pmol/L) Standard Error 5.42	79.00 Picomoles per liter (pmol/L) Standard Error 5.46	86.55 Picomoles per liter (pmol/L) Standard Error 5.59

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Percentage change in HOMA-IR from week 0 to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a subject's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered Insulin sensitive, 0.5-1.4: considered Healthy, Above 1.8: considered Early insulin resistance; Above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. Endpoint was evaluated based on data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=96 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=99 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=96 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=93 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=94 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Percentage Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)	-0.05 Percentage change of HOMA-IR Standard Deviation 5.83	-0.60 Percentage change of HOMA-IR Standard Deviation 8.42	-1.09 Percentage change of HOMA-IR Standard Deviation 3.37	-0.72 Percentage change of HOMA-IR Standard Deviation 1.94	-2.12 Percentage change of HOMA-IR Standard Deviation 7.32	-0.91 Percentage change of HOMA-IR Standard Deviation 2.38	-0.71 Percentage change of HOMA-IR Standard Deviation 7.10

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The full analysis set included all randomised participants. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change between the value of HOMA-beta cell function collected at Week 26 and HOMA-beta cell function collected at Week 0 is presented. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 * insulin (micro international units per milliliter (µIU/mL)) / fasting plasma glucose (millimoles per liter (mmol/L)) - 3.5. HOMA-beta score ranges from minus infinity to infinity (no limits). The higher the score the better beta-cell function for HOMA-beta. The endpoint was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period.

Outcome measures

Measure	Cagrilintide 0.3 mg n=95 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=95 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=96 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=89 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=93 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Homeostatic Model Assessment of Beta-cell Function (HOMA-beta)	-10.7 Percentage of Beta Cell Function Standard Deviation 94.1	-20.0 Percentage of Beta Cell Function Standard Deviation 136.9	-18.3 Percentage of Beta Cell Function Standard Deviation 89.8	-29.9 Percentage of Beta Cell Function Standard Deviation 54.8	-39.7 Percentage of Beta Cell Function Standard Deviation 101.2	16.3 Percentage of Beta Cell Function Standard Deviation 75.1	-26.0 Percentage of Beta Cell Function Standard Deviation 122.6

SECONDARY outcome

Timeframe: From week 0 to week 32

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment.

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or used a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=101 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Number of Treatment-emergent Adverse Events (TEAEs)	335 Events	291 Events	361 Events	449 Events	460 Events	470 Events	276 Events

SECONDARY outcome

Timeframe: From week 0 to week 32

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment.

An AE was any untoward medical occurrence in a clinical trial participant administered or used a medicinal product, whether or not considered related to the medicinal product or usage. Serious AE is an AE that resulted in death, life threatening, persistent or significant incapacity or substantial disruption of ability to conduct normal life functions, hospitalization or prolongation of existing hospitalization, congenital anomaly or birth defect, important medical events that may not result in death, be life threatening, or require hospitalization. All SAEs reported in the below table are TESAEs. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=101 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Number of Treatment-emergent Serious Adverse Events (TESAEs)	8 Events	3 Events	8 Events	6 Events	4 Events	4 Events	4 Events

SECONDARY outcome

Timeframe: From week 0 to week 32

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment.

Number of participants with occurrence of anti-drug antibodies towards cagrilintide from randomisation from week 0 to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period. This endpoint is applicable only for the cagrilintide treatment arms.

Outcome measures

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Number of Participants With Occurrence of Anti-drug Antibodies Towards Cagrilintide	51 Participants	54 Participants	52 Participants	75 Participants	75 Participants	—	—

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analysed = Number of participants who contributed to the analysis.

Blood pressure was measured in a sitting position after 5 minutes of rest. The end point is evaluated while the subject is treatment-adherent. A participant is treatment adherent until the first time of non-adherence defined as: a) the participant has not been dosed with trial product within the prior 14 days; b) the participant has received other weight management drug or bariatric surgery c) the participant has not reached target dose at a pre-specified week d) After the pre-specified evaluation week for the target dose, the participant has not received the target dose +/- 10 % within the prior 14 days. This endpoint is applicable only for the cagrilintide treatment arms.

Outcome measures

Measure	Cagrilintide 0.3 mg n=63 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=63 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=58 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=66 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=68 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=47 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Diastolic Blood Pressure (DBP)	-2.2 millimeter of mercury (mmHg) Standard Deviation 5.9	0.8 millimeter of mercury (mmHg) Standard Deviation 5.0	-1.3 millimeter of mercury (mmHg) Standard Deviation 6.0	-1.2 millimeter of mercury (mmHg) Standard Deviation 5.5	-1.8 millimeter of mercury (mmHg) Standard Deviation 6.3	-2.6 millimeter of mercury (mmHg) Standard Deviation 5.5	—

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analysed = Number of participants who contributed to the analysis.

Blood pressure was measured in a sitting position after 5 minutes of rest. The end point is evaluated while the subject is treatment-adherent. A participant is treatment adherent until the first time of non-adherence defined as: a) the participant has not been dosed with trial product within the prior 14 days; b) the participant has received other weight management drug or bariatric surgery c) the participant has not reached target dose at a pre-specified week d) After the pre-specified evaluation week for the target dose, the participant has not received the target dose +/- 10 % within the prior 14 days. This endpoint is applicable only for the cagrilintide treatment arms.

Outcome measures

Measure	Cagrilintide 0.3 mg n=63 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=63 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=58 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=66 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=68 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=47 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Systolic Blood Pressure (SBP)	-4.9 mmHg Standard Deviation 8.7	-0.9 mmHg Standard Deviation 8.1	-4.9 mmHg Standard Deviation 9.7	-5.0 mmHg Standard Deviation 8.4	-6.2 mmHg Standard Deviation 8.5	-3.8 mmHg Standard Deviation 7.1	—

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in pulse from week 0 to week 26 is presented. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=94 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=91 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=92 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=95 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=88 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=86 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Pulse	-2.1 beats per minute Standard Deviation 8.4	-0.6 beats per minute Standard Deviation 8.4	-1.2 beats per minute Standard Deviation 9.1	-2.0 beats per minute Standard Deviation 10.2	-4.5 beats per minute Standard Deviation 9.2	1.6 beats per minute Standard Deviation 9.1	-0.1 beats per minute Standard Deviation 8.5

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Number analysed = Number of participants who contributed to the analysis.

In the below table, hsCRP data at week 0 and at week 26 is presented. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=101 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=101 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in High Sensitivity C-reactive Protein (hsCRP) Week 26	3.5 milligrams per liter (mg/L) Standard Deviation 3.5	3.4 milligrams per liter (mg/L) Standard Deviation 3.0	4.6 milligrams per liter (mg/L) Standard Deviation 8.8	4.0 milligrams per liter (mg/L) Standard Deviation 5.5	3.4 milligrams per liter (mg/L) Standard Deviation 4.0	3.5 milligrams per liter (mg/L) Standard Deviation 3.4	3.9 milligrams per liter (mg/L) Standard Deviation 5.3
Change in High Sensitivity C-reactive Protein (hsCRP) Week 0	4.5 milligrams per liter (mg/L) Standard Deviation 6.7	4.6 milligrams per liter (mg/L) Standard Deviation 3.9	4.5 milligrams per liter (mg/L) Standard Deviation 5.8	5.8 milligrams per liter (mg/L) Standard Deviation 7.2	5.4 milligrams per liter (mg/L) Standard Deviation 7.5	4.7 milligrams per liter (mg/L) Standard Deviation 4.1	4.6 milligrams per liter (mg/L) Standard Deviation 6.0

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment.

Due to the assay development issue faced by the laboratory, the Plasminogen Activator Inhibitor-1 (PAI-1) activity (mg/L) was not performed in the study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in renin activity from week 0 to week 26 is presented. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=89 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=92 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=92 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=92 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=91 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=84 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=84 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Renin Activity	2 nanograms per milliliter per hour Standard Deviation 12	0 nanograms per milliliter per hour Standard Deviation 4	1 nanograms per milliliter per hour Standard Deviation 9	1 nanograms per milliliter per hour Standard Deviation 10	1 nanograms per milliliter per hour Standard Deviation 8	0 nanograms per milliliter per hour Standard Deviation 5	0 nanograms per milliliter per hour Standard Deviation 5

SECONDARY outcome

Timeframe: From baseline (week 0) to week 26

Population: The safety analysis set included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analysed = Number of participants who contributed to the analysis.

Change in aldosterone from week 0 to week 26 is presented. The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Outcome measures

Measure	Cagrilintide 0.3 mg n=94 Participants Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=92 Participants Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=92 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=94 Participants Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=88 Participants Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Pooled Placebo n=85 Participants Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Change in Aldosterone	0.8 nanograms per deciliter (ng/dL) Standard Deviation 5.4	0.8 nanograms per deciliter (ng/dL) Standard Deviation 6.3	0.7 nanograms per deciliter (ng/dL) Standard Deviation 5.2	2.2 nanograms per deciliter (ng/dL) Standard Deviation 7.1	1.1 nanograms per deciliter (ng/dL) Standard Deviation 5.9	1.0 nanograms per deciliter (ng/dL) Standard Deviation 8.2	0.5 nanograms per deciliter (ng/dL) Standard Deviation 5.1

Adverse Events

Cagrilintide 0.3 mg

Serious events: 6 serious events

Other events: 59 other events

Deaths: 0 deaths

Cagrilintide 0.6 mg

Serious events: 2 serious events

Other events: 58 other events

Deaths: 0 deaths

Cagrilintide 1.2 mg

Serious events: 7 serious events

Other events: 72 other events

Deaths: 0 deaths

Cagrilintide 2.4 mg

Serious events: 3 serious events

Other events: 62 other events

Deaths: 0 deaths

Cagrilintide 4.5 mg

Serious events: 4 serious events

Other events: 76 other events

Deaths: 0 deaths

Liraglutide 3.0 mg

Serious events: 4 serious events

Other events: 65 other events

Deaths: 0 deaths

Placebo Pool

Serious events: 3 serious events

Other events: 45 other events

Deaths: 0 deaths

Serious adverse events

Measure	Cagrilintide 0.3 mg n=101 participants at risk Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 participants at risk Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 participants at risk Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Placebo Pool n=101 participants at risk Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Gastrointestinal disorders Abdominal hernia	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Arthritis bacterial	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Asthma	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Hepatobiliary disorders Biliary colic	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Campylobacter gastroenteritis	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Nervous system disorders Cerebrovascular accident	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Hepatobiliary disorders Cholelithiasis	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/99 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Musculoskeletal and connective tissue disorders Chondrocalcinosis pyrophosphate	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Vascular disorders Deep vein thrombosis	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Blood and lymphatic system disorders Deficiency anaemia	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Psychiatric disorders Delirium	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Investigations Electrocardiogram QT prolonged	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gallbladder adenoma	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/99 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Musculoskeletal and connective tissue disorders Intervertebral disc disorder	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Injury, poisoning and procedural complications Ligament injury	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/100 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Injury, poisoning and procedural complications Meniscus injury	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/100 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Non-cardiac chest pain	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/99 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Pilonidal cyst	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Pneumonia	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenocarcinoma	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/100 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Eye disorders Retinal detachment	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Nervous system disorders Syncope	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/99 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Nervous system disorders Transient ischaemic attack	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/99 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Other adverse events

Measure	Cagrilintide 0.3 mg n=101 participants at risk Participants were to receive once weekly subcutaneous (s.c.) injection of 0.3 milligrams (mg) cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 0.6 mg n=100 participants at risk Participants were to receive once weekly s.c. injection of 0.6 mg cagrilintide for 26 weeks, using NovoPen® 4 pen-injector.	Cagrilintide 1.2 mg n=102 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 1.2 mg was reached: 0.6 mg (week 0) and 1.2 mg (week 2 to week 26).	Cagrilintide 2.4 mg n=102 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 2.4 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4 to week 26).	Cagrilintide 4.5 mg n=101 participants at risk Participants were to receive once weekly s.c. injection of cagrilintide for 26 weeks, using NovoPen® 4 pen-injector. Participants initially received 0.6 mg of cagrilintide and the dose was then escalated every other week until the target dose of 4.5 mg was reached: 0.6 mg (week 0), 1.2 mg (week 2), 2.4 mg (week 4), 4.5 mg (week 6 to week 26).	Liraglutide 3.0 mg n=99 participants at risk Participants were to receive once daily s.c. injection of liraglutide for 26 weeks, using PDS290 pen-injector. Participants initially received 0.6 mg of liraglutide and the dose was then escalated every other week until the target dose of 3.0 mg was reached: 0.6 mg (week 0), 1.2 mg (week 1), 1.8 mg (week 2), 2.4 mg (week 3), 3.0 mg (week 4 to week 26).	Placebo Pool n=101 participants at risk Participants were to receive once weekly / once daily s.c. injection of placebo matched to cagrilintide / liraglutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg / 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg ) for 26 weeks respectively.
Gastrointestinal disorders Abdominal distension	3.0% 3/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/100 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/102 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/102 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.1% 5/99 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Abdominal pain	2.0% 2/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.0% 5/100 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.9% 4/102 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.9% 3/102 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.0% 5/101 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/99 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Abdominal pain upper	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/100 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/102 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.9% 4/102 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.1% 7/99 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Musculoskeletal and connective tissue disorders Arthralgia	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.0% 5/100 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.9% 3/102 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/102 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/101 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/99 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Constipation	10.9% 11/101 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.0% 9/100 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.8% 8/102 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	16.7% 17/102 • Number of events 17 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	20.8% 21/101 • Number of events 25 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	26.3% 26/99 • Number of events 30 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Metabolism and nutrition disorders Decreased appetite	4.0% 4/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.0% 9/100 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.8% 8/102 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	12.7% 13/102 • Number of events 13 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	16.8% 17/101 • Number of events 18 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.1% 9/99 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Diarrhoea	14.9% 15/101 • Number of events 22 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	10.0% 10/100 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.8% 8/102 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	17.6% 18/102 • Number of events 20 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	18.2% 18/99 • Number of events 28 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	8.9% 9/101 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Nervous system disorders Dizziness	7.9% 8/101 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/100 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.8% 8/102 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	8.8% 9/102 • Number of events 14 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	8.9% 9/101 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.1% 5/99 • Number of events 11 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Dry mouth	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/100 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/102 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.1% 5/99 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Dyspepsia	3.0% 3/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/100 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.9% 3/102 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.9% 3/102 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	10.1% 10/99 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Fatigue	7.9% 8/101 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.0% 5/100 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.8% 8/102 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.8% 10/102 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	19.8% 20/101 • Number of events 21 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	8.1% 8/99 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Nervous system disorders Headache	9.9% 10/101 • Number of events 15 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.0% 5/100 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	10.8% 11/102 • Number of events 13 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	10.8% 11/102 • Number of events 17 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	13.1% 13/99 • Number of events 24 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	11.9% 12/101 • Number of events 22 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Injection site erythema	5.0% 5/101 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/100 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/102 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/102 • Number of events 23 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	16.8% 17/101 • Number of events 22 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/99 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Injection site pruritus	5.0% 5/101 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/100 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.9% 4/102 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/102 • Number of events 11 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/99 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Injection site rash	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/100 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/102 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/102 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/101 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/99 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
General disorders Injection site reaction	4.0% 4/101 • Number of events 26 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/100 • Number of events 10 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/102 • Number of events 30 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	11.8% 12/102 • Number of events 44 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.9% 10/101 • Number of events 39 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	1.0% 1/99 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Nasopharyngitis	5.9% 6/101 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.0% 9/100 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	12.7% 13/102 • Number of events 14 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.9% 4/102 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	10.1% 10/99 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	9.9% 10/101 • Number of events 12 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Nausea	19.8% 20/101 • Number of events 26 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	27.0% 27/100 • Number of events 32 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	36.3% 37/102 • Number of events 45 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	31.4% 32/102 • Number of events 41 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	46.5% 47/101 • Number of events 61 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	39.4% 39/99 • Number of events 56 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	17.8% 18/101 • Number of events 26 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/101 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/100 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/102 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.98% 1/102 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/99 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.9% 7/101 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Upper respiratory tract infection	4.0% 4/101 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/100 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/102 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/102 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	5.9% 6/101 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.1% 7/99 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Infections and infestations Urinary tract infection	0.99% 1/101 • Number of events 1 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.0% 7/100 • Number of events 9 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.9% 3/102 • Number of events 3 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.9% 4/102 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.0% 4/99 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	2.0% 2/101 • Number of events 2 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
Gastrointestinal disorders Vomiting	5.9% 6/101 • Number of events 6 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	6.0% 6/100 • Number of events 7 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	4.9% 5/102 • Number of events 5 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	8.8% 9/102 • Number of events 11 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	7.9% 8/101 • Number of events 8 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	20.2% 20/99 • Number of events 31 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.	3.0% 3/101 • Number of events 4 • From week 0 to week 32 Results are based on the safety analysis set which included all randomised participants exposed to at least one dose of randomised treatment. All presented adverse events are treatment emergent adverse events (TEAEs). TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.

Additional Information

Clinical Reporting Anchor and Disclosure (1452)

Novo Nordisk A/S

Phone: (+1) 866-867-7178

Email: clinicaltrials@novonordisk.com

Results disclosure agreements

• Principal investigator is a sponsor employee At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.
• Publication restrictions are in place

Restriction type: OTHER